EGFR and lung cancer: In advanced lung cancer patients with EGFR-positive mutations, there was no significant difference in PFS (11.0 [95% CI: 9.2–12.8] vs. 20.0 [95% CI: 2.4–37.6] months, HR: 1.560 [95% CI: 0.656–3.708], p = 0.18) and OS (39.8 [95% CI: 36.3–43.2] months vs. not reached, HR: 2.827 [95% CI: 0.381–20.991], p = 0.29) between first-line use of first-generation or third-generation EGFR-tyrosine kinase inhibitors (EGFR-TKIs) (Figure 3A,B).